Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

275

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2027

Conditions

Non-Small Cell Lung CancerALK-positiveSAF-189s

Interventions

OTHER

Drug: Foritinib Succinate

SAF-189s: 160 mg QD, 21 days a cycle

OTHER

Drug: Crizotinib

Crizotinib: 250 mg BID, 21 days a cycle

Trial Locations (1)

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

INDUSTRY